Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform
ConclusionsOur review identified studies with very limited sample size for the three major drugs (miltefosine, L-AmB, and pentavalent antimony), while the number of patients combined across studies suggest that the IPD platform would be valuable. With the support of relevant stakeholders, the global PKDL community and sufficient financing, a PKDL IPD platform can be realised. This will allow for exploration of different aspects of treatment safety and efficacy, which can potentially guide future healthcare decisions and clinical practices.
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Sauman Singh-Phulgenda Source Type: research
More News: Abelcet | Bangladesh Health | Clinical Trials | Databases & Libraries | Dermatology | Endemics | India Health | International Medicine & Public Health | Nepal Health | Parasitology | Science | Statistics | Study | Sudan Health | Tropical Medicine